GlassScriptPhysician profile
Olivia Yambem
NPI 1972859080
$3,354.44
in general payments reported to CMS, 2019-2025
29 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $270 · 2021: $658 · 2022: $578 · 2023: $368 · 2024: $469 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,542 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,541.63 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.43 | 2021-2025 | Ubrelvy |
| Biogen, INC. | $435.52 | 2019-2025 | Vumerity, Tysabri |
| Ucb, INC. | $313.42 | 2019-2025 | Briviact, Rystiggo |
| Alexion Pharmaceuticals, INC. | $252.42 | 2019-2025 | Ultomiris |
| Sk Life Science, INC. | $210.06 | 2020-2023 | |
| Pfizer INC. | $206.16 | 2023-2025 | |
| Neurelis, INC. | $123.98 | 2020-2022 | |
| Boston Scientific Corporation | $123.80 | 2021 | |
| Argenx US, INC. | $118.36 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Nevro Corp. | $117.57 | 2021 | |
| Tanabe Pharma America, INC. | $109.37 | 2020-2024 | |
| Medtronic Vascular, INC. | $104.50 | 2019 | |
| Lilly USA, LLC | $94.08 | 2020-2025 | Kisunla, Emgality |
| Lundbeck LLC | $86.89 | 2025 | Vyepti |
| Allergan, INC. | $85.56 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $71.97 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $65.94 | 2021 | |
| Medtronic USA, INC. | $62.07 | 2019 | |
| Horizon Therapeutics Plc | $37.92 | 2022-2023 | Uplizna |
| Genzyme Corporation | $34.42 | 2019 | |
| Acorda Therapeutics, INC | $31.38 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $27.46 | 2025 | |
| Genentech USA, INC. | $24.80 | 2024 | Ocrevus, Enspryng |
| Otsuka America Pharmaceutical, INC. | $20.85 | 2025 | Rexulti |
| Tg Therapeutics, INC. | $20.68 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.18 | 2022 | |
| Acadia Pharmaceuticals INC | $17.21 | 2025 | Nuplazid |
| Grt US Holding, INC. | $15.89 | 2022 | |
| Amgen INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Yambem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.